The endothelial deprotection hypothesis for lupus pathogenesis by Prechl, J & Czirjak, L
F1000Research
Open Peer Review
, University of TennesseeMarko Radic
Health Science Center USA
, New York UniversityGregg Silverman
Langone Medical Center USA







The endothelial deprotection hypothesis for lupus pathogenesis:
the dual role of C1q as a mediator of clearance and regulator of
 endothelial permeability[version 1; referees: 2 approved, 1
approved with reservations]
József Prechl , László Czirják3
Diagnosticum Zrt, Budapest, 1047, Hungary
MTA-ELTE Immunology Research Group, Budapest, 1117, Hungary
Department of Rheumatology and Immunology, Clinic Center, University of Pécs, Pécs, 7632, Hungary
Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous multifactorial
systemic autoimmune disease afecting several organs. SLE can start relatively
early in life and results in impaired quality of life and shortened life expectancy
because of a gradual disease progression leading to cardiovascular, renal and
neoplastic disease. The basic mechanisms of the pathogenesis of the disease
stil remain to be clarified. It is clear that complement proteins play a key and
complex role in the development of SLE. Complement component C1q has
been known to be a fundamental component of lupus development, but most
explanations focus on its role in apoptotic debris removal. Importantly, C1q was
recently found to play a key role in the maintenance of vascular endothelial
integrity.
We suggest that apoptotic products, endothelial cels and extracelular matrix
components, which display negatively charged moieties, compete for binding
to molecules of the innate humoral immune response, like C1q. Genetic or
acquired factors leading to an increased load of apoptotic cel debris and
decrease or absence of C1q therefore interfere with the regulation of
endothelial permeability and integrity. Furthermore, we suggest that lupus is the
net result of an imbalance between the two functions of immune clearance and
vascular endothelial integrity maintenance, an imbalance triggered and
sustained by autoimmunity, which skews C1q consumption by IgG-mediated
complement classical pathway activation on autoantigens. In this triangle of
innate clearance, autoimmunity and endothelial integrity, C1q plays a central
role.
Hence, we interpret the pathogenesis of lupus by identifying three key
components, namely innate immune clearance, autoimmunity and endothelial
integrity and we establish a link between these components based on the
protective role that innate clearance molecules play in endothelial renewal. By
including the vasoprotective role of C1q in the interpretation of SLE
development we atempt to provide novel explanations for the symptoms,
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Introduction
A  database search for the  word “lupus” in the title  of  biomedi-
cal publications brings up 39,306 papers as of the writing of this 
manuscript.  Thus, there is an abundance  of experimental and 
clinical research  data  on systemic lupus erythematosus (SLE),  yet 
the comprehensive etiopathogenesis  of this  group  of  heterogeneous 
diseases with multifactorial origin is stil unknown (Figure 1). SLE 
is an enigmatic  disease,  with a range  of  manifestations. Indeed, 
curently systemic lupus erythematosus is classified,  but  not 
diagnosed,  on the  basis  of the coexistence  of several alterations 
from a list  of criteria1,2. Immune complexes containing IgG and 
complement are found deposited in various tissues and are respon-
sible for inflammatory processes causing skin rash, mucosal ulcers, 
arthritis,  nephritis, and serositis.  Hematological changes include 
diverse cytopenias,  while immunological tests show antibodies 
against nuclear material, dsDNA, Sm antigen and phospholipids3.
In an atempt to simultaneously monitor antibody and complement 
binding to  various autoantigens,  we  have  developed a functional 
immunomics approach4,5 alowing a complex analysis of serologi-
cal events in SLE. Interestingly, we observed that copious amounts 
of complement  products are  fixed  by  nucleic acids  but  not  other 
negatively charged molecules in SLE patients with decreased com-
plement C4 levels6 (and manuscript in preparation), which finaly 
led us to formulate the hypothesis presented below. In this paper, 
we atempt to colect al the pieces of knowledge of the lupus puz-
zle and place them next to each other in a way that a novel picture 
emerges. We  hope that this  hypothesis  wil stimulate  discussions 
along a novel course and finaly wil result in a beter understanding 
of the lupus syndrome.
The pieces of the puzzle we already have
We can arange most of the curently accepted mechanisms of lupus 
pathology in three main sets of factors: impaired clearance, autoim-
munity and vascular injury. The elements of these particular proc-
esses are  highly interconnected  but for  didactic reasons  we  wil 
discuss them within one of these categories.
Impaired immune clearance
Increased load  of celular  debris.  The initiation  of  pathological 
autoimmune responses requires autoantigens to reach and trigger 
lymphocytes in the lymphoid organs. Celular debris released from 
dying and dead cels is thought to be the most important source of 
self-antigen in lupus. One of the most widely used animal models 
of human SLE is the MRL/lpr mouse strain. These animals cary 
multiple susceptibility  genes,  which control lymphoproliferation 
and apoptosis7, and spontaneously  develop a lupus-like  disease 
with antinuclear antibody production and nephritis. Interestingly, in 
human autoimmune lymphoproliferative syndrome (ALPS), where 
apoptotic signaling is impaired, some  of the symptoms  observed 
in SLE also appear8, underlining the role of this factor. Direct evi-
dence for the role of apoptotic load is also available, since increased 
apoptosis of monocytes9, neutrophils10, lymphocytes11 and endothe-
lial cels (EC)12 has been described in SLE patients.
Impairment  of  apoptotic  debris removal.  Cels  undergoing  pro-
grammed cel  death are cleared from the  body  without inducing 
inflammation. This is part of the physiological tissue maintenance 
and regeneration events continuously occuring in the body. Dead 
cels, apoptotic blebs and debris are recognized by several soluble 
molecules and cel surface receptors, al promoting uptake by tissue 
macrophages and dendritic cels. This silent removal localy prevents 
inflammation and systemicaly the  development  of autoreactive 
lymphocytes13. Inefficient removal of apoptotic cel debris in lupus14 
leads to the clonal expansion of autoreactive lymphocytes, with both 
B cels and T cels involved.  Nucleosomes  become accessible  on 
the cel surface15, exposing negatively charged nucleic acid contain-
ing complexes. NETosis, a form of programmed cel death recently 
described in  neutrophil  granulocytes,  has also  been implicated 
as a source of celular debris that contributes to lupus pathogenesis16.
The complement system plays an important role in apoptotic cel 
removal: C1q binds to negatively charged molecules like phosphati-
dyl serine and cardiolipin17 and polyanionic targets, like DNA18,19. 
Various cels display receptors for C1q and help silent phagocytosis 
Figure 1. Systemic lupus erythematosus is a heterogeneous group of multifactorial diseases. The development of lupus is influenced by 
genetic factors, controling individual variability especialy with regard to the immune system and also with regard to physiology. Anatomical 
features may determine organ damage and source of autoantigens. Environmental factors can act upon al these elements, and may be 
the component we could try to modulate with the aim of preventing disease development. SLE, systemic lupus erythematosus; BCR, B-cel 
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of apoptotic cels  opsonized  by  C1q13,20,21.  The classical  pathway 
of complement is activated; deposited C4 and C3 fragments are then 
recognized by the CR3 of myeloid cels, a receptor encoded by lupus 
susceptibility gene ITGAM. The alelic variant of CR3 associated 
with lupus shows impaired phagocytotic and adhesion function22.
Hereditary complement  deficiencies.  Early complement compo-
nents have long been known to play a key role in lupus development. 
Genetic deficiency of C1q is the strongest susceptibility factor for 
lupus23, with close to 100% of the deficient subjects showing signs 
of the syndrome. Deficiency in the components involved in the later 
steps of classical pathway activation, C2 and C4, also predisposes 
to lupus development, albeit with lower probability. Interestingly, 
people  with lupus show a secondary  deficiency  of these  particu-
lar complement components suggesting the consumption of these 
proteins  by factors  playing a role in  disease  pathogenesis.  These 
intriguing relations between complement and lupus have been dis-
cussed in depth by excelent reviews24,25.
Complement  deficiency  due to consumption. Immunoglobulins 
undergo a conformational change upon antigen binding. This event 
coupled with immobilization and provision of affixed C1q binding 
sites promotes the binding of the C1 complex. The atachment of 
C1 wil activate C1r and C1s, initiating the complement cascade26. 
The fact that DNA specific immunoglobulins trigger complement 
activation to such an extent that the systemic consumption is meas-
urable as decreased C4, C3 and CH50 levels has been known for 
decades27. The measurement of these parameters forms part of the 
diagnostic routine even today, because secondary complement defi-
ciency in lupus is associated with disease activity28. Complement is 
also consumed by being deposited on blood cels in the circulation 
of lupus patients, a fact that is beginning to be exploited for diag-
nostic purposes29.
Development of autoimmunity
Breaking  of tolerance.  Lymphocytes  go through several check-
points during their development, ensuring that self-reactivity is kept 
within a rational range30. The process results in immunological tol-
erance to self-antigens. Tolerance can be broken by increased load 
of apoptotic cel debris reaching the secondary lymphoid organs31, 
increased  propensity for  positive selection  of  B cels32, the  pres-
ence  of  molecular  paterns in autoantigen that activates  Tol-like 
receptors33, the production of cytokines regulating B-cel develop-
ment34. The breaking of tolerance is characterized by the produc-
tion of immunoglobulins specific for the autoantigens which induce 
autoimmunity, therefore these autoantibodies can be used as disease 
markers and also to identify the source of the autoantigens.
Development  of  autoantibodies.  Once tolerance against self is 
broken, antibodies against  various  nuclear components appear, 
including various forms of DNA, RNA, nucleosome complexes and 
nuclear proteins35. Autoantibodies are detectable before the clinical 
onset of SLE36 and with the development of organ damage various 
specific autoantibodies appear in the circulation37. These can involve 
various extractable nuclear antigens38, phospholipids39, complement 
proteins40,41 and even cytokines like BAFF42. The composition of the 
immune complexes has important consequences regarding its cel 
activating properties: DNA in the immune complexes that are formed 
upon the  production  of IgG antibodies stimulates  plasmocytoid 
dendritic cels, which in turn release type I interferons, promoting 
tissue injury43. The antigen-driven development and appearance of 
high affinity  double-stranded  DNA specific IgG is considered a 
halmark of systemic lupus erythematosus44.
Vascular injury
Circulating immune complexes bind to vessel wal. In lupus, imm-
une complexes are found in the circulation, atached to vessel wals 
and  deposited  perivascularly.  Binding to capilary  wal endothe-
lium  was shown to  be  dependent  on the  presence  of  C1q in the 
immune complexes  C1q45–47.  Thus,  once immunity is triggered 
against autoantigens, the  presence  of  both autoreactive IgG and 
autoantigen in the circulation wil lead to the formation of C1q con-
taining immune complexes. Circulating immune complexes with char-
acteristic components are found in various autoimmune diseases48.
Neutrophil granulocytes and FcγRs as efectors of inflammatory 
injury. Neutrophil granulocytes roling along the vessel wal bind 
to the IgG component  of  deposited ICs  via  Fc  gamma receptors. 
This binding, as modeled in our functional antibody assay49, wil 
trigger adhesion and activation of the cel. Neutrophil granulocytes 
secrete type I interferon and play important roles in the initiation 
and perpetuation of the disease50. Fc gamma receptors displayed by 
the granulocyte play intricate roles in the recognition and uptake of 
IgG immune complexes and the induction of NETosis51. Dysregula-
tion of NET formation itself has also been suggested to play a role 
in lupus pathogenesis52.
Endothelial cel (EC)  dysfunction in lupus.  Lupus  patients  have 
a high risk of developing cardiovascular disease. Endothelial dys-
function, one of the key factors of atherogenesis, can be triggered 
by  various endothelium  damaging factors  present in lupus53.  The 
efects  of cytokines, inflammatory cels and immune complexes 
are combined  with compromised endothelial functions resulting 
in increased atherogenicity in lupus53.  Endothelial repair is also 
compromised by a decrease in the number of bone marow derived 
endothelial cel progenitors54. Interestingly, C1q and mannose bind-
ing lectin (MBL), recognition  molecules  of the classical and lec-
tin pathways of complement activation, respectively, help remove 
atherogenic lipoproteins55, establishing a link  between  C1q  defi-
ciency and cardiovascular disease development in lupus. Increased 
vascular endothelial permeability resulting in edema, infiltration of 
inflammatory cels and  deposition  of immune complexes are the 
commonly observed histological features of the disease.
Coagulation  and thrombosis  defects in lupus.  SLE  patients are 
susceptible to cardiovascular morbidity and mortality56. Abnormal 
coagulation and thrombus formation is associated with the presence 
of anti-phospholipid antibodies, exemplified  by anti-cardiolipin, 
anti-β2-glycoprotein and lupus anticoagulant antibodies57.  These 
autoantibodies  have  been suggested to  directly cause endothelial 
injury or promote atherogenesis by altering lipoprotein metabolism58.
The missing piece: molecules of innate immunity 
contribute to endothelial integrity
One important  question that  has  been left largely  unanswered so 
far is why and how exactly are the vascular wal and surounding 
tissues damaged? How do the above named three main categories, 
impaired clearance, autoimmunity and vascular injury interact with 
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each other? We propose that the answer lies in the protective role 
that innate clearance molecules play in endothelial renewal.
The globular head of complement C1q binds to negatively charged 
molecules like DNA59 and cardiolipin17, and also to immunoglobu-
lins  mainly  via ionic interactions60.  C1q  has also  been shown to 
bind  heparan sulfate61, a component  of the extracelular  matrix 
(ECM) and of the surface structures of adherent cels62. Thus, C1q 
beyond its role in the clearance of apoptotic cel debris could also be 
involved in endothelial cel interactions with the ECM. Indeed, C1q 
has been shown to play a role in vascular regeneration by binding 
to endothelial cels and promoting endothelial adhesion and spread-
ing63 and exert  proangiogenic efects like stimulation  of endothe-
lial proliferation, migration and permeability64. With these multiple 
roles of C1q in mind, we propose the folowing two scenarios, one 
describing events occuring in the presence of intact endothelium 
and another for leaky endothelium.
Proposed role of C1q in transendothelial transport
In a  healthy adult  male, the endothelium is  quiescent65.  Signifi-
cant amounts of C1q bind to EC only in tissues with discontinuous 
endothelium. Discontinuous endothelium is found at sites of transen-
dothelial trafficking and is characterized by the fusion of the luminal 
and abluminal plasma membranes, the presence of pores of various 
diameters and  high  heparan sulfate content  of the  glycocalyx66,67. 
Discontinuous endothelium is divided into sinusoidal and fenestrated 
types.  Sinusoidal endothelium lines  bone  marow sinuses, splenic 
and liver sinuses; fenestrated endothelium covers capilary wals in 
kidney  glomeruli, in the  gastrointestinal tract, in endocrine  glands 
and in the choroid  plexus65. In  healthy adult females  of the child-
bearing age the endothelium is subject to the efects of factors that 
regulate cyclic renewal of the endometrium, an event accompanied 
by vascular regeneration68.
The  glycocalyx is a layer  of  macromolecules,  mostly  glycosa-
minoglycans,  decorating the surface  of  ECs.  Heparan sulfate 
constitutes more than 50% of the glycosaminoglycan pool in EC, 
localizing especialy in cave-like structures (caveolae)69 and the 
fenestrae66,  both areas  playing  primary roles in transendothelial 
transport and  filtration, respectively. We envisage that  C1q  binds 
to heparan sulfate-rich regions on the luminal surface of EC and is 
also efficiently transported to the abluminal side into the tissues.
Proposed role of C1q in paracelular endothelial leakage
If the integrity of the endothelium is disrupted, the subendothelial 
lamina  becomes exposed to the  blood  plasma.  When  ECs are in 
the  process  of cel  division  or  death, large  pores  with  diameters 
reaching 1 micrometer are formed in the endothelium, as a result 
of celular discontinuity70. Upon exposure, subendothelial colagen 
immediately  binds to several  molecules from the  blood  plasma, 
triggering repair, coagulation and thrombocyte binding. This event 
remains silent as long as the endothelium is only modestly damaged. 
Even though the physiological turnover of EC is low71 subendothe-
lial colagen can  be exposed  whenever and  wherever endothelial 
cels die. The renewal process is restricted in time and space, unless 
massive endothelial cel apoptosis is triggered by external factors, 
such as UV radiation. C1q or C1q containing IC can pass through 
these leaky junctions and deposit in the ECM, where heparan sul-
fate is an essential  proteoglycan component72.  Since  C1q is an 
eat-me-silently signal for  myeloid cels, as  discussed above,  C1q 
deposition  protects these areas  of endothelial regeneration from 
myeloid cel-mediated damage, until integrity is reconstituted.
Based  on the above  observations  we  hypothesize that sufficient 
amounts  of free  C1q should  be available in the  blood in  order to 
maintain endothelial trafficking, integrity and renewal. Free serum 
C1q protects exposed colagen from triggering atachment, activa-
tion and extravasation  of  monocytes and  neutrophil  granulocytes 
during endothelial renewal.
Potential role of other molecules with similar binding patern
However, C1q is actualy not the only multivalent molecule which 
binds  negatively charged  moieties. In addition there is  – at least 
–  one  other  molecule  with the ability to  bind to apoptotic cels 
multivalently.  Natural IgM (nIgM)  molecules,  which are  pro-
duced without a clearly identifiable antigenic stimulus, have been 
shown to  promote the clearance  of apoptotic cels in  mice73 and 
enhance phagocytic clearance of host cels74. IgM against dsDNA 
was shown to be protective in a murine autoimmune model75. The 
general immunological  protective  properties  of  natural IgM  were 
recently reviewed  by  Grönwal et  al.76,77. Anti-apoptotic cel IgM 
antibodies  bind  C1q and  promote clearance  by  phagocytes78. An 
interesting aspect of IgM is that it can bypass the classical activation 
pathway by binding MBL and induce C4b deposition via MASPs. 
MBL  deficient  mice  displayed impaired apoptotic cel clearance, 
without overt signs of autoimmunity, suggesting an alternative role 
for clearance by the lectin pathway79. Natural IgM binding and the 
ensuing events lead to the recognition and removal of apoptotic cels 
without activating the phagocytic cels74. The fact that antibodies of 
the IgM class do bind to colagen and this binding is decreased in 
lupus  patients  has  been reported6,80. The  question that remains to 
be answered is whether it is nIgM that binds to colagen. It is also 
intriguing whether other molecules of the innate humoral immune 
system, such as pentraxins and colectins may play similar roles.
In summary, multivalent molecules with a propensity to bind nega-
tively charged targets and the ability to initiate complement activa-
tion are consumed by apoptotic cels, immune complexes, EC and 
the ECM. As long as these molecules are available in excess this 
competition wil go unnoticed. Once this balance is tipped patho-
logical events start to take place.
Puting the pieces together: the endothelial 
deprotection hypothesis
If  C1q  binds  negatively charged  molecules then those  mole-
cules compete for  C1q  binding.  Competition for  C1q  binding  by 
deoxyribose and  heparan sulfate  has  been experimentaly con-
firmed61.  Thus,  negatively charged components  of the exposed 
nuclear content  of  dying cels and  of the  EC fenestrae  or the 
exposed subendothelial matrix can al bind C1 complex from the 
circulation. Physiologicaly there is sufficient amount of C1 avail-
able and a  balance exists  between the  vessel  wal and celular 
debris. This binding results in tightly controled classical comple-
ment pathway activation, leading to the production of C4b. Other 
factors controling complement activation also  bind to  negatively 
charged  molecules; these include complement factor  H,  C4bBP81 
amongst several other recognition molecules of the innate humoral 
immune system, like pentraxins82 and surfactant proteins83,84. These 
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molecules regulate further activation  of the complement cascade, 
the production of anaphylatoxins and the activation of surounding 
and recruited cels.  Opsonized apoptotic  debris  wil therefore  be 
silently removed  by  macrophages (Figure  2A). The fact that  not 
only the absence of C1q but also functional C1q deficiency leads 
to lupus development85 suggests that initiation of the classical path-
way activation is required for the removal  of celular  debris and 
prevention of development of immune complex disease.
This  balanced  binding to  EC, subendothelial colagen and celu-
lar debris can be tipped basicaly by three main factors: decrease 
in C1q levels, increased load of apoptotic cels and increased col-
lagen exposure.  Genetic  deficiency in  C1q is accompanied  by 
highly increased (more than 90%) likelihood of developing SLE86. 
Increased cel  death can  be triggered  by ionizing radiation  or  by 
drugs  with cytotoxic efects87. Inefficient  phagocytic capacity  of 
CR3 polymorphic variant r77h88, a lupus susceptibility factor, may 
also increase apoptotic load. Increased colagen exposure can be the 
result of endothelial apoptosis induced by sunlight but physiologi-
cal turnover of the endothelium is also accompanied by macromo-
lecular permeability and access to the subendothelial lamina89.
As a result  of  one  or  more  of these factors, celular  debris  wil 
reach secondary lymphoid  organs, triggering immunity against 
self-molecules, including DNA. IgM is first produced, which may 
help restore the  balance  by enhancing apoptotic  debris removal 
via complement activation (Figure 2B). This is in agreement with 
the findings of Li et al., who reported increased IgM reactivity to 
several autoantigens in patients with incomplete lupus erythemato-
sus syndromes35. The generation of DNA specific IgG further tips 
the  balance towards  opsonization  of celular  debris, taking away 
more  C1q, leaving exposed subendothelial colagen  unprotected 
(Figure 2C). Furthermore, circulating complexes of nuclear mate-
rial, IgG and  C1q wil  bind to exposed colagen by  nature of the 
multivalent C1q molecule and difuse into the tissues. Alternatively, 
in organs with discontinuous endothelium, immune complexes wil 
bind to the fenestrae and  be transported into the tissue.  Deposi-
tion  of immune complexes containing IgG  wil trigger activation 
of monocytes and neutrophil granulocytes, atracted by C3 and C5 
derived anaphylatoxins  of the alternative  pathway. This results in 
damage to the vessel wal itself, to increased permeability and to 
IgG-mediated damage to the tissues (Figure 2D).
To summarize, impaired clearance of cel debris and immune com-
plexes together  with  pathological anti-nuclear antibodies consume 
C1q, an important vascular regeneration factor, from the circulation, 
by directing it to immune complexes and apoptotic cels. In turn, not 
free but immune complex-bound C1q wil atach to EC and exposed 
subendothelial colagen. IgG  wil trigger inflammation instead  of 
regeneration. According to this scenario, dsDNA IgG triggers inflam-
mation,  while  dsDNA IgM can act against it,  by competing  with 
IgG for dsDNA binding. Indeed, the ratio of dsDNA IgG to IgM 
has been shown to be a good indicator of renal damage in SLE90,91.
Interpreting the lupus syndrome in light of the 
hypothesis
Sex diference in susceptibility
Even though lupus can develop in both men and women, 90% of 
patients diagnosed with the disease are women, most of them being 
in the childbearing age92. How hormones contribute to this skewed 
susceptibility is not defined. Our hypothesis emphasizes the role of 
vascular endothelial renewal in the pathogenesis of SLE, pointing 
to sex diferences in angiogenesis.
In fact, angiogenesis is a critical component  of endometrial 
renewal. Various hormones and growth factors interact during the 
formation  of  new  vessels, including  vascular endothelial  growth 
factor (VEGF)68,93.  VEGF is  produced in  ovarian tissues  during 
the menstrual cycle and regulates vascular remodeling and repair. 
VEGF is a  permeability factor as  wel, its topical administration 
can induce the  development  of fenestrations in the endothelium 
of smal venules and capilaries94. Estradiol itself can also directly 
increase  permeability95 and act indirectly96  by  modulating VEGF 
production in endothelial cels. As  highlighted above and further 
discussed  below, fenestration, accessibility  of the subendothelial 
lamina  promotes the  deposition  of  both  bare  C1q and  nIgM and 
C1q containing immune complexes. This would render women of 
the childbearing age, with functioning ovaries, more susceptible to 
immune complex deposition and vascular damage in SLE.
Organ damage in SLE
Our  hypothesis suggests that anatomical sites  with  discontinuous 
endothelium and tissues where colagen in the subendothelial lam-
ina is exposed wil be more vulnerable to immune complex induced 
damage. There is one more important aspect we have to consider: 
what is the source of the autoantigen that wil induce autoimmu-
nity? Keeping with the notion that in lupus it is the material from 
dead cels that induces autoimmune response  we  need to locate 
the source of apoptotic cels. Here we consider two main catego-
ries: cel  death  within the circulation and  outside  of the circula-
tion. Within the circulation it is the corpuscles in the blood97 and 
endothelial cels12 that are sources of celular debris. Actualy we 
wil also consider the bone marow as a source of apoptotic debris 
within the circulation because of the high rate of apoptotic death 
during lymphocyte development and the sinusoidal structure of the 
endothelium in the tissue. Apoptotic antigens within the circulation 
wil be distributed by the blood flow throughout the body. Immune 
complexes formed from this material wil be deposited anywhere 
where there is blood flow, and preferentialy where blood flow is 
high, the endothelium is  discontinuous and  where subendothelial 
colagen is more accessible. We suggest that renal, bone marow, 
joint, serosal and synovial, and partly skin damage in lupus is medi-
ated by this route and constitutes the core components of SLE.
Apoptotic cels that come into contact with blood also initiate coag-
ulation events98. Therefore in addition to lipids that become exposed 
on apoptotic cels, phospholipid-binding proteins (β2-glycoprotein) 
and components of the coagulation cascade wil serve as autoanti-
gens targeted by the immune response. Anti-cardiolipin antibodies 
and lupus anticoagulant could  be  produced as the result  of these 
pathological events99, and are responsible for the secondary anti-
phospholipid antibody syndrome in SLE.
Outside of the circulation, basicaly meaning in the tissues, apop-
totic cels and their fragments and antigen presenting cels carying 
and processing those wil reach the secondary lymphoid organs first. 
Antibodies generated in the lymphoid organs wil enter the circula-
tion and immune complexes may or may not be formed, depending 
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Figure  2. The  endothelial  deprotection  hypothesis. Maintenance  of  endothelial integrity  and  clearance  of  celular  debris  both requires 
multimeric innate molecules (C1q, nIgM) with the ability to bind anionic surfaces (A). C1q binds to fenestrated regions of the endothelial 
cel  and to  colagen  exposed  due to leaky  endothel junctions. Increased  use  of these innate  molecules  by the  clearance  mechanism, 
or  deficiency  of these  molecules  shifts this  balance,  which results in  celular  debris reaching the lymphoid  organs (B).  This triggers the 
production of IgM against the autoantigens. Induced autoreactive IgM binds to apoptotic autoantigens, activates the complement system 
and  promotes  clearance.  Sustained  autoantigenic  stimulus  and  geneticaly  determined  clearance  deficiency  coupled  with tendency  of 
mounting inflammatory immune responses wil result in the production of IgG against the tissue derived autoantigens (C). Immune complexes 
containing IgG and C1q wil bind to the vascular wal, since free C1q levels are low and circulating immune complexes wil outcompete 
them. Deposited immune complexes containing IgG recruit white blood cels with Fcγ receptors, which can trigger cel activation, release 
of inflammatory cytokines, frustrated phagocytosis, NETosis (D). Immune complexes and autoantibodies can penetrate the tissues via the 
damaged endothelium, causing organ specific damage. Sustained inflammation leads to ireversible organ damage.
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on the presence or absence of antigen. Once these autoantibodies 
appear, they could sustain organ specific damage and disease course 
by binding to their targets thanks to increased permeability by gen-
eral impairment in endothelial regeneration.
Photosensitivity. Cutaneous manifestations of SLE are often linked 
to exposure to sunlight or artificial sources of ultraviolet (UV) light. 
Malar rash, the buterfly shaped erythematous lesion on the face is 
a classical sign of lupus. It may be present in about 50% of SLE 
patients at the time  of the  diagnosis100 and is  part  of the  general 
photosensitivity  observed in  SLE.  UV-light induced apoptosis  of 
keratinocytes is thought to be a source of celular debris that pro-
motes the induction of rheumatic diseases101. Actualy endothelial 
cels are  quite sensitive to radiation-induced, ceramide-mediated 
apoptotic cel  death102–104. We speculate that  UV light  penetrating 
the epidermis may cause endothelial damage in dermal capilaries. 
Dead endothelial cels wil be removed inefficiently in the relative 
absence of C1q and nIgM, while the exposed subendothelial lamina 
wil  be less  protected  by these  molecules. Increased  paracelular 
leakage and transcelular trafficking in activated  EC  would result 
in increased deposition of IC, edema and extravasation of myeloid 
cels and the appearance of rash. Additionaly, the entry of apoptotic 
endothelial cels12 or their products containing nuclear material and 
proinflammatory mediators105 into the circulation may contribute to 
disease flares triggered by UV exposure.
Renal involvement.  SLE can lead to the  development  of lupus 
nephritis,  which is  one  of the  most  disabling complications106. 
The  kidneys are  prone to immune complex  mediated  damage for 
at least two reasons. It is the organ with the second highest blood 
flow rate107 and the endothelium is fenestrated, leaving access to 
C1q bearing immune complexes. Apoptotic debris that is generated 
within the circulation or enters the circulation wil have a very high 
chance of ending up in the glomeruli. Should these complexes con-
tain IgG, the necessary component for triggering inflammation wil 
be present. Other factors, such as DNAse activity may modulate the 
severity and prognosis of nephritis108.
Synovitis and serositis. Besides ionizing radiation mechanical inju-
ries  may also  negatively influence endothelial integrity.  Synovial 
and serosal membranes are rich with blood circulation and are con-
tinuously exposed to  micromechanical injuries  due to the  move-
ment of the joints and inner organs, respectively. We suggest that 
the healing of these microinjured sites would be slower and accom-
panied by edema and celular infiltration, because of the deposition 
of circulating immune complexes. These microinjuries may there-
fore be responsible for arthritis, pleuritis and pericarditis in SLE.
Bone marrow involvement. The bone marow is a site of intensive 
cel proliferation and cel death. Lymphocyte development involves 
selection steps when useless or harmful clones are deleted by pro-
grammed cel death. Any defect in the clearance of apoptotic cels is 
therefore expected to influence homeostasis in this tissue. Addition-
aly, it is a site where there is intensive migration via the endothelial 
layer in both directions, facilitated by a special endothelial struc-
ture: the sinusoidal endothelium. We suggest that this tissue would 
be vulnerable to immune complex deposition and inflammation. In 
SLE patients abnormal bone marow histology is observed109. Com-
parative analysis of gene expression revealed upregulation of genes 
involved in cel  death and  granulopoesis in active  SLE  patients, 
confirming the role of apoptosis and granulocytes in the pathogen-
esis of the disease110. We suggest that cytopenias, the detection of 
which constitute  pilars  of the  diagnostic algorithm  of  SLE2, are 
the consequence of abnormal bone marow function, in addition to 
specific antibody mediated direct damage.
Consequences for diagnostic eforts
Classification  of systemic lupus erythematosus relies  on clinical 
examination,  hematological tests and serological test.  The  pres-
ence of dsDNA specific IgG is quite specific but less sensitive for 
the identification  of  SLE  patients6.  Decreased complement levels 
and complement activity are also used but not specific for the dis-
ease. Indeed our hypothesis suggests that there is no single protein 
marker, which could be used alone, because a state of imbalance 
can only be assessed by the measurement of the diferent compo-
nents characterizing the degree of imbalance. The measurement of 
free  C1q  or  C1 complex and also  of  nIgM could  be assessed for 
incorporation into the set of laboratory tests characterizing autoim-
mune conditions. Alternatively, instead of measuring the levels of 
individual proteins, a functional test that is capable of gauging the 
degree of endothelial damage, the propensity of immune complex 
deposition and inflammatory cel reactions al together, could  be 
used for assisting diagnosis.
Implications for future therapy and prevention of SLE
The causal therapy for lupus, based on the endothelial deprotection 
hypothesis, would be the restoration of endothelial integrity by the 
introduction or induction of C1q or nIgM. In the case of genetic C1q 
deficiency replacement therapy seems to be the logical solution111. 
Indeed, hematopoetic stem cel transplantation was recently shown 
to be successful treatment for hereditary C1q immunodeficiency112. 
For replacement therapy the administration of C1q or natural IgM 
is a potential solution. Immunoglobulin preparations for high dose 
intravenous immunoglobulin therapy contain mainly IgG and exert 
their efects via pathways related to IgG. However, successful man-
agement  of  SLE  with IgM enriched intravenous immunoglobulin 
(IVIG) has also been reported113, providing support for the benefi-
cial role of nIgM.
It is tempting to speculate that the  production  of  natural IgM, 
endothelial turnover and integrity and innate clearance are influ-
enced by environmental factors such as nutrition and lifestyle114,115 
or factors produced by the mucosal microbiome, like vitamin K116. 
If so, we could even look for prevention strategies in light of this 
hypothesis. The relatively low concordance of SLE in monozygotic 
twins117 implies that there is ample room for the modulation of envi-
ronmental efects.
Concluding remarks and future directions
We propose an interaction scheme for SLE pathogenesis with three 
key components, each of these contributing to disease development 
by their mutual interactions (Figure 3). These components are innate 
immune clearance, adaptive immune response quality and endothe-
lial integrity. The endothelial deprotection hypothesis assumes that 
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Figure 3. The lupus triangle in health and disease. C1q and natural IgM are gatekeepers that ensure innate immune clearance of apoptotic 
celular debris and immune complexes, and also maintain endothelial integrity (A). Under physiological conditions these processes do not 
interfere with each other. Major abnormality in one or more of these processes, or combinations of minor abnormalities lead to imbalance, the 
breakdown of these gates and the development of lupus erythematosus (B). Depending on the contribution of these factors lupus wil have 
diferent colors and shades, which define distinct disease entities or subtypes within such entities.
the mechanisms of innate clearance and endothelial integrity share 
molecules like C1q and nIgM, therefore the two systems can inter-
fere. We suggest that SLE is the net result of an imbalance between 
these two systems, which is aggravated by the development of auto-
reactive antibodies, leading to the leakage  of immune complexes 
from the circulation and the triggering of inflammation in the vessel 
wals and in the tissues.
It wil be imperative to create sets and networks of genetic factors 
that  underlie these events and  upon that superimpose the  protein 
interactions to create a framework for further interpretation of cel-
lular and immunological  processes leading to  various forms and 
manifestations of lupus. We speculate that other systemic autoim-
mune diseases wil share some of these components while also pos-
sessing distinct other susceptibility factors to create a continuum of 
diseases with overlaps. We hope that this hypothesis wil serve the 
further understanding of lupus and these other related diseases as 
wel, leading to novel medical approaches and improvement in the 
quality of life of al those sufering from these conditions.
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leakage. These events could be compromised by the reduced levels of C1q that are associated with
lupus or with DNA-anti-DNA immune complexes (IC). The proposed hypothesis is appealing because it
may account for the early steps in pathogenesis. It may also provide a convincing connection to sites of
vascular disease and IC deposition. One aspect that is not thoroughly covered is the deposition of C1q at
sites of endothelial discontinuity. These are presented as areas that arise from the apoptotic death of
endothelial cels which could expose underlying ECM. However, previous reports of apoptosis in a
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layer. This needs to be discussed more fuly. In addition, the primary references describing the role of
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data supporting the role of C1q in regulating endothelial permeability, healing and renewal is
sparse. This is main the reason for caling this work a hypothesis and not yet a theory. The reports
of C1q influencing endothelial renewal however do fit into the overal emerging big picture of the
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